基于药物载体的心肌梗死治疗进展  

Drug Carriers in the Treatment of Myocardial Infarction

作　　者：邵敬津 刘佳 潘莹[2] 罗玉梅 SHAO Jingjin;LIU Jia;PAN Ying;LUO Yumei(Guangdong Medical University,Zhanjiang 524000,Guangdong,China;Longgang People’s Hospital,Shenzhen 518172,Guangdong,China)

机构地区：[1]广东医科大学,广东湛江524000 [2]深圳市龙岗区人民医院,广东深圳518172

出　　处：《心血管病学进展》2022年第10期902-905,共4页Advances in Cardiovascular Diseases

摘　　要：心肌梗死作为全球主要死因之一,是由冠状动脉闭塞引起所供应的心肌严重而持久缺血死亡所致。药物载体具有良好的生物相容性、机械力性、导电性和化学性能,是一种安全有效的药物递送系统,在心肌梗死治疗上有潜在价值,现综述药物载体在心肌梗死治疗方面的研究进展。Myocardial infarction,as one of the leading causes of death worldwide,is caused by severe and persistent ischemia of the supplying myocardium caused by coronary occlusion.The drug carrier has good biocompatibility,mechanical properties,electrical conductivity and chemical properties.It is a safe and effective drug delivery system and has potential value in the treatment of myocardial infarction.This paper reviews the research progress of drug carriers in the treatment of myocardial infarction.

关 键 词：心肌梗死 药物载体 血管生成因子 

分 类 号：R542.22[医药卫生—心血管疾病]